Patient characteristics

CharacteristicsNumber (%)
Age< 65
≥ 65
66 (54.1)
56 (45.9)
GenderMale
Female
75 (61.5)
47 (38.5)
ECOG0–1
2–3
77 (63.1)
45 (36.9)
Lauren typeColonic
Diffuse
Mixed
Not known
29 (23.8)
53 (43.4)
15 (12.3)
25 (20.5)
MSI statusMSI-H
MSS
Not known
27 (22.1)
71 (58.1)
24 (19.8)
PD-L1 (CPS)PD-L1 negative
PD-L1 CPS 1–9
PD-L1 CPS ≥ 10
Not known
7 (5.7)
57 (46.7)
14 (11.5)
44 (36.1)
HER2Positive
Negative
Not known
19 (15.7)
88 (72.7)
15 (11.6)
Primary tumorPresence
Surgically removed
70 (57.4)
52 (42.6)
Number of organs with metastases1–2
≥ 3
77 (63.1)
45 (36.9)
Metastatic sitesLiver
Lungs
Peritoneum
Lymphatic nodes
Bones
Other
46 (38)
16 (12.4)
54 (44.6)
64 (52.1)
12 (9.9)
15 (12.4)
Line of immunotherapyFirst-line
Second-line
Third-line
Fourth-line and subsequent
6 (4.9)
58 (47.5)
40 (32.8)
18 (14.8)
Number of lines after immunotherapy0
1
2
≥ 3
78 (64.5)
22 (18.2)
17 (13.2)
5 (4.1)

ECOG: Eastern Cooperative Oncology Group; MSI: microsatellite instability; MSI-H: high microsatellite instability; MSS: microsatellite stable; PD-L1: programmed death-ligand 1; CPS: combined positive score; HER2: human epidermal growth factor receptor 2